Citius Oncology, Inc. — Income Charts
1 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$4M
Cost of Revenue
$789K
Gross Profit
$3M
R&D
$1M
Operating Income
$-5M
EBITDA
$-5M
Interest Expense
$46K
Interest Income
$28K
Other Income/Expense
$0
Pretax Income
$-5M
Tax Provision
$264K
Net Income
$-6M
Gross Margin
80.0%
Operating Margin
-133.2%
Net Margin
-140.3%
Effective Tax Rate
-5.0%
Deferred Tax Liabilities
$3M
ETR (Continuing Operations)
—
ETR State + Local (pp)
—
ETR Foreign Differential (pp)
—
Income YoY Variation
17.9%
Income QoQ Variation
—